Dr Mazyar Shadman speaks to ecancer about the results from the final analysis of the ALPINE randomised phase 3 study.
This study demonstrated that zanubrutinib had a superior progression-free survival (PFS) compared to ibrutinib for the treatment of relapsed/refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma (R/R CLL/SLL).
Dr Shadman discusses the study design and results.
He concludes by talking about the future of the study and how these results can impact clinical practice.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
16 май 2023
